101 related articles for article (PubMed ID: 29434605)
1. MHC Intratumoral Heterogeneity May Predict Cancer Progression and Response to Immunotherapy.
Romero I; Garrido C; Algarra I; Chamorro V; Collado A; Garrido F; Garcia-Lora AM
Front Immunol; 2018; 9():102. PubMed ID: 29434605
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy eradicates metastases with reversible defects in MHC class I expression.
Garrido C; Romero I; Berruguilla E; Cancela B; Algarra I; Collado A; García-Lora A; Garrido F
Cancer Immunol Immunother; 2011 Sep; 60(9):1257-68. PubMed ID: 21553283
[TBL] [Abstract][Full Text] [Related]
3. Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations.
Aptsiauri N; Carretero R; Garcia-Lora A; Real LM; Cabrera T; Garrido F
Cancer Immunol Immunother; 2008 Nov; 57(11):1727-33. PubMed ID: 18491093
[TBL] [Abstract][Full Text] [Related]
4. Rejection versus escape: the tumor MHC dilemma.
Garrido F; Ruiz-Cabello F; Aptsiauri N
Cancer Immunol Immunother; 2017 Feb; 66(2):259-271. PubMed ID: 28040849
[TBL] [Abstract][Full Text] [Related]
5. The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible "hard" lesions.
Garrido F; Algarra I; García-Lora AM
Cancer Immunol Immunother; 2010 Oct; 59(10):1601-6. PubMed ID: 20625726
[TBL] [Abstract][Full Text] [Related]
6. Increased efficiency of immunotherapy using irradiated tumor cells.
Wu JM; Fitzgerald J; Sonis S; Ravikumar T; Wilson R
Cancer Immunol Immunother; 1987; 24(1):68-71. PubMed ID: 3815419
[TBL] [Abstract][Full Text] [Related]
7. Author Correction: Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors.
Zakrzewski JL; Suh D; Markley JC; Smith OM; King C; Goldberg GL; Jenq R; Holland AM; Grubin J; Cabrera-Perez J; Brentjens RJ; Lu SX; Rizzuto G; Sant'Angelo DB; Riviere I; Sadelain M; Heller G; Zúñiga-Pflücker JC; Lu C; van den Brink MRM
Nat Biotechnol; 2024 Apr; 42(4):674. PubMed ID: 38531977
[No Abstract] [Full Text] [Related]
8. Intratumoral heterogeneity in cancer progression and response to immunotherapy.
Vitale I; Shema E; Loi S; Galluzzi L
Nat Med; 2021 Feb; 27(2):212-224. PubMed ID: 33574607
[TBL] [Abstract][Full Text] [Related]
9. Expanded Alternatives of CRISPR-Cas9 Applications in Immunotherapy of Colorectal Cancer.
Arroyo-Olarte R; Mejía-Muñoz A; León-Cabrera S
Mol Diagn Ther; 2024 Jan; 28(1):69-86. PubMed ID: 37907826
[TBL] [Abstract][Full Text] [Related]
10. Primary and acquired resistance to first-line therapy for clear cell renal cell carcinoma.
Astore S; Baciarello G; Cerbone L; Calabrò F
Cancer Drug Resist; 2023; 6(3):517-546. PubMed ID: 37842234
[TBL] [Abstract][Full Text] [Related]
11. Tapasin-mediated editing of the MHC I immunopeptidome is epitope specific and dependent on peptide off-rate, abundance, and level of tapasin expression.
Boulanger DSM; Douglas LR; Duriez PJ; Kang Y; Dalchau N; James E; Elliott T
Front Immunol; 2022; 13():956603. PubMed ID: 36389776
[TBL] [Abstract][Full Text] [Related]
12. Tumor MHC class I expression alters cancer-associated myelopoiesis driven by host NK cells.
Neo SY; Jing X; Tong L; Tong D; Gao J; Chen Z; De Los Santos MC; Burduli N; De Souza Ferreira S; Wagner AK; Alici E; Rolny C; Cao Y; Lundqvist A
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36283735
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness.
Panagi M; Pilavaki P; Constantinidou A; Stylianopoulos T
Theranostics; 2022; 12(14):6106-6129. PubMed ID: 36168619
[TBL] [Abstract][Full Text] [Related]
14. Tumor Heterogeneity and Consequences for Bladder Cancer Treatment.
Lavallee E; Sfakianos JP; Mulholland DJ
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771460
[TBL] [Abstract][Full Text] [Related]
15. Combined treatment with epigenetic agents enhances anti-tumor activity of T cells by upregulating the ACRBP expression in hepatocellular carcinoma.
Ge YY; Zhang QM; Liu C; Zeng X; Nong WX; Chen F; Bi SQ; Guo WW; Luo B; Xie XX
Am J Transl Res; 2021; 13(7):7591-7609. PubMed ID: 34377237
[TBL] [Abstract][Full Text] [Related]
16. MHC heterogeneity and response of metastases to immunotherapy.
Algarra I; Garrido F; Garcia-Lora AM
Cancer Metastasis Rev; 2021 Jun; 40(2):501-517. PubMed ID: 33860434
[TBL] [Abstract][Full Text] [Related]
17. Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation.
Dhatchinamoorthy K; Colbert JD; Rock KL
Front Immunol; 2021; 12():636568. PubMed ID: 33767702
[TBL] [Abstract][Full Text] [Related]
18. Could Extracellular Vesicles Contribute to Generation or Awakening of "Sleepy" Metastatic Niches?
Hernández-Barranco A; Nogués L; Peinado H
Front Cell Dev Biol; 2021; 9():625221. PubMed ID: 33738282
[TBL] [Abstract][Full Text] [Related]
19. HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy.
Anderson P; Aptsiauri N; Ruiz-Cabello F; Garrido F
Cell Mol Immunol; 2021 Mar; 18(3):556-565. PubMed ID: 33473191
[TBL] [Abstract][Full Text] [Related]
20. Major Histocompatibility Complex Genes as Therapeutic Opportunity for Immune Cold Molecular Cancer Subtypes.
Karpiński P; Łaczmański Ł; Sąsiadek MM
J Immunol Res; 2020; 2020():8758090. PubMed ID: 33282963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
